Memory impairment in patients with late-onset major depression: The effect of antidepressant therapy

Gallassi, Roberto; Sarro, Rita Di; Morreale, Angela; Amore, Mario

doi:10.1016/j.jad.2006.01.018

Cited by 103 publications

(85 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fluoxetine has been reported to improve memory in patients with impaired cognition in depression (Levkovitz et al, 2002;Gallassi et al, 2006) and mild cognitive impairment (Mowla et al, 2007). Based on our findings, there may be translational potential in treating patients with mesial temporal lobe epilepsy with mild hippocampal sclerosis and a history of status epilepticus, with fluoxetine in order to improve spatial and perhaps verbal learning, since the pattern of spatial learning and memory deficits was very similar in patients and animals.…”

Section: Relevance To Patients With Mesial Temporal Lobe Epilepsysupporting

confidence: 55%

Fluoxetine restores spatial learning but not accelerated forgetting in mesial temporal lobe epilepsy

Barkas

Redhead

Taylor

et al. 2012

Brain

View full text Add to dashboard Cite

Learning and memory dysfunction is the most common neuropsychological effect of mesial temporal lobe epilepsy, and because the underlying neurobiology is poorly understood, there are no pharmacological strategies to help restore memory function in these patients. We have demonstrated impairments in the acquisition of an allocentric spatial task, in patients with unilateral hippocampal sclerosis. We also show that patients have accelerated forgetting of the learned spatial task and that this is associated with damage to the non-dominant hippocampal formation. We go on to show a very similar pattern of chronic allocentric learning and accelerated forgetting in a status epilepticus model of mesial temporal lobe epilepsy in rats, which is associated with reduced and abnormal hippocampal neurogenesis. Finally, we show that reversal of the neurogenic deficit using fluoxetine is associated with reversal of the learning deficit but not the accelerated forgetting, pointing to a possible dissociation in the underlying mechanisms, as well as a potential therapeutic strategy for improving hippocampal-dependant learning in patients with mesial temporal lobe epilepsy.

show abstract

Section: Relevance To Patients With Mesial Temporal Lobe Epilepsysupporting

confidence: 55%

Fluoxetine restores spatial learning but not accelerated forgetting in mesial temporal lobe epilepsy

Barkas

Redhead

Taylor

et al. 2012

Brain

View full text Add to dashboard Cite

show abstract

“…44 A more recent systematic review and meta-analysis identified 20 studies of 102,172 individuals from 8 countries and found very similar results for AD with pooled odds ratio estimates of 2.03 (1.73, 2.38) for 9 case-control studies and 1.90 (1.55, 2.33) for 11 cohort studies. 45 Several RCTs have found that treatment of depression in older adults results in improved cognitive function, [46][47][48][49] although some studies have found no improvement, 50 and cognitive function typically remains below normal levels. In addition, some types of anti-depressant therapies-particularly those with anti-cholinergic properties-may impair or worsen cognitive function.…”

Section: Depressionmentioning

confidence: 99%

O3‐06‐06: The Projected impact of risk factor reduction on Alzheimer's disease prevalence

Barnes

Yaffe

2011

Alzheimer's & Dementia

View full text Add to dashboard Cite

There are currently approximately 33.9 million individuals with Alzheimer's disease (AD) worldwide, and prevalence is expected to triple over the next 40 years. The goal of this review was to summarize the evidence regarding seven potentially modifiable AD risk factors: diabetes, midlife hypertension, mid-life obesity, smoking, depression, low educational attainment and physical inactivity. In addition, we projected the impact of risk factor reduction on AD prevalence by calculating population attributable risks (PARs, the percent of cases attributable to a given factor) and the number of AD cases that could potentially be prevented by 10% and 25% risk factor reductions worldwide and in the US. Together, these factors contributed to up to half of AD cases globally (17.2 million) and in the US (2.9 million). A 10%-25% reduction in all seven risk factors could potentially prevent as many as 1.1-3.0 million cases worldwide and 184,000-492,000 cases in the US.

show abstract

“…Yet in late-onset depression, cognitive deficits frequently persist, albeit to a lesser extent, following recovery from the episode, suggesting that they are not simply the result of depressed mood but instead are both 'state and trait' deficits (Nebes et al, 2003;Gallassi et al, 2006). There is also evidence that severity of cognitive deficits increases with severity of depression, regardless of age or education (Elderkin-Thompson et al, 2003).…”

Section: Cognitive Deficitsmentioning

confidence: 99%

Late-onset depression: issues affecting clinical care

Variend¹,

Gopal²

2008

Adv. psychiatr. treat

View full text Add to dashboard Cite

A growing body of evidence suggests that late-onset depression (depression occurring for the first time in later life) differs from early-onset (recurrent) depression in terms of clinical features, aetiology, neuroanatomical substrates and prognosis. Some evidence suggests that late-onset depression is more associated with somatic symptoms, cognitive deficits, cerebral structural abnormalities, vascular disease ('vascular depression') and poorer treatment outcomes than is early-onset depression. Both general adult and old age psychiatrists face the challenges of managing late-onset depression. In this article we attempt to clarify specific issues relating to late-onset depression in terms of clinical features, aetiology, treatment response and prognosis.Hannele Variend is an academic specialist registrar in general adult psychiatry working in the Yorkshire Deanery. Y. Vishnu Gopal is a consultant psychiatrist at the Hartington Unit (Royal Hospital, Chesterfield S44 5BL, UK. Email: vgopal@doctors.org.uk). His interests include assessment and management of cognitive dysfunctions.

show abstract

Memory impairment in patients with late-onset major depression: The effect of antidepressant therapy

Cited by 103 publications

References 37 publications

Fluoxetine restores spatial learning but not accelerated forgetting in mesial temporal lobe epilepsy

Fluoxetine restores spatial learning but not accelerated forgetting in mesial temporal lobe epilepsy

O3‐06‐06: The Projected impact of risk factor reduction on Alzheimer's disease prevalence

Late-onset depression: issues affecting clinical care

Contact Info

Product

Resources

About